Sitavig

Chickenpox, Encephalitis, Herpes Simplex, Neutropenia + 18 more
Treatment
20 Active Studies for Sitavig

What is Sitavig

AcyclovirThe Generic name of this drug
Treatment SummaryAcyclovir is an antiviral drug used to treat different types of herpes, including herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. It is often the first treatment prescribed for these viruses and can be given to children as young as 6 years old. Acyclovir was approved by the FDA in 1982.
Zoviraxis the brand name
image of different drug pills on a surface
Sitavig Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zovirax
Acyclovir
1982
496

Effectiveness

How Sitavig Affects PatientsAcyclovir is a drug that stops the spread of viruses associated with herpes, such as cold sores. It works by blocking the DNA replication of the virus. Acyclovir is usually safe to take, even in large doses, and so it has a wide range of doses it can be taken at.
How Sitavig works in the bodyAcyclovir works by interfering with the virus's ability to reproduce. When a virus infects a cell, it uses an enzyme called thymidine kinase to turn acyclovir into a form called acyclovir monophosphate. This form is then converted to a diphosphate form by guanylate kinase. The diphosphate form is then converted to the active form, acyclovir triphosphate, by enzymes like pyruvate kinase. Acyclovir triphosphate has a high affinity for the virus's DNA polymerase, and

When to interrupt dosage

The prescribed dosage of Sitavig is contingent upon the diagnosed condition, including Cytomegalovirus Infections, grave Genital herpes and Herpes simplex type I resurgence. The measure of dosage is contingent on the technique of delivery (e.g. Cream - Topical or Injection, powder, lyophilized, for solution - Intravenous) as detailed in the table below.
Condition
Dosage
Administration
Bone Marrow Transplant
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Neutropenia
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Genital Herpes
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Herpes Simplex Infections
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
VZV re-activation
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Chickenpox
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Communicable Diseases
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Immunocompromised
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Herpes Genitalis
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Shingles
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Keratitis, Herpetic
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Cytomegalovirus Infections
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
prophylaxis of VZV re-activation
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Herpes Labialis
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Genital Herpes
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Herpes Simplex
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Herpes Labialis
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Bell Palsy
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
Encephalitis, Herpes Simplex
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical
prophylaxis of HSV re-activation
200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL
Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution - Intravenous, Injection, solution, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Tablet - Buccal, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Warnings

Sitavig has one contraindication, thus it should not be blended with the ailments enumerated in the following table.Sitavig Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Acyclovir may interact with Pulse Frequency
There are 20 known major drug interactions with Sitavig.
Common Sitavig Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Acyclovir.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Neomycin.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Acyclovir.
Tenofovir
Major
Acyclovir may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Acyclovir may increase the nephrotoxic activities of Tenofovir alafenamide.
Sitavig Toxicity & Overdose RiskOverdosing on Cyclosporin can cause agitation, loss of consciousness, seizures, and excessive sleepiness. These effects are more likely to occur in those who have not been monitored for fluid levels or kidney function. Treatment for Cyclosporin overdose should involve supportive care and addressing the symptoms.
image of a doctor in a lab doing drug, clinical research

Sitavig Novel Uses: Which Conditions Have a Clinical Trial Featuring Sitavig?

34 clinical studies are presently assessing the potential of Sitavig to prophylactically inhibit Varicella Zoster Virus (VZV) reactivation and reduce the incidence of Immunocompromised and Communicable Diseases.
Condition
Clinical Trials
Trial Phases
Encephalitis, Herpes Simplex
0 Actively Recruiting
Herpes Simplex Infections
0 Actively Recruiting
Herpes Genitalis
0 Actively Recruiting
VZV re-activation
0 Actively Recruiting
Chickenpox
4 Actively Recruiting
Phase 4, Phase 3
Neutropenia
5 Actively Recruiting
Phase 1, Phase 2, Phase 4, Phase 3
Cytomegalovirus Infections
0 Actively Recruiting
Genital Herpes
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Bone Marrow Transplant
27 Actively Recruiting
Not Applicable, Phase 2, Early Phase 1, Phase 1
Immunocompromised
3 Actively Recruiting
Not Applicable, Phase 1
Keratitis, Herpetic
0 Actively Recruiting
prophylaxis of HSV re-activation
0 Actively Recruiting
Shingles
4 Actively Recruiting
Phase 2, Phase 1
Herpes Simplex
0 Actively Recruiting
Herpes Labialis
0 Actively Recruiting
Genital Herpes
0 Actively Recruiting
prophylaxis of VZV re-activation
0 Actively Recruiting
Bell Palsy
0 Actively Recruiting
Herpes Labialis
0 Actively Recruiting

Sitavig Reviews: What are patients saying about Sitavig?

4.7Patient Review
7/21/2020
Sitavig for Cold Sore
This drug is on the pricey side, but it cleared my cold sore quickly and I haven't had one in over 18 months.
1.7Patient Review
2/10/2015
Sitavig for Cold Sore
Valtrex was more effective for me when taken at the first sign of a cold sore.
1Patient Review
6/7/2016
Sitavig for Cold Sore
This pill is way too expensive for how ineffective it is. I had to keep taking oral pills even after starting this treatment, and I tried it twice just to give it a chance. No dice.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sitavig

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How much does Sitavig cost?

"The average retail price of Sitavig is $1,202.11, 23% off the average retail price of $1,202.11. Compare herpes virus nucleosides."

Answered by AI

How long does it take for Sitavig to dissolve?

"When the tablet is applied to the gums, it needs to stay there for 6 hours, but it may take up to 14 hours to dissolve."

Answered by AI

What is Sitavig used for?

"SITAVIG is a prescription medicine that is used to treat cold sores in adults who have normal immune systems."

Answered by AI

Is Sitavig covered by insurance?

"Your doctor can prescribe a drug called Sitavig. The cost of the drug depends on your insurance coverage, any prescription deductibles you have, and your prescription copay. There is a patient access card for Sitavig which may reduce the copay for qualifying patients."

Answered by AI

Clinical Trials for Sitavig

Image of Princess Margaret Cancer Centre, University Health Network in Toronto, Canada.

Psychoeducation for Caregivers of Bone Marrow Transplant Patients

18+
All Sexes
Toronto, Canada
Background: Caregivers of patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for hematological malignancies face significant challenges that can impact their well-being. This study aims to evaluate the feasibility and acceptability of an adapted psychoeducational intervention(PEI) designed to support these caregivers. Methods: This study will recruit caregivers of alloHCT patients. Participants will be enrolled during pre-transplant clinic visits, typically 2-4 weeks before the scheduled transplant. The intervention consists of eight sessions over 12 weeks, delivered via Microsoft Teams by a nurse facilitator. In the adapted PEI, participants will learn stress management, coping strategies, energy management, goal-setting, communication skills, and support resource access through interactive exercises. Data Collection: Participants will complete questionnaires at three time points: pre-intervention, one month post-transplant, and three months post-transplant. The final assessment will include additional questions about feasibility, acceptability and the initial efficacy of the adapted PEI. Outcomes: The primary outcomes will be the feasibility and acceptability of the adapted psychoeducational intervention (PEI). Secondary outcomes will include initial efficacy of the adapted PEI on caregiver outcomes such as depression, anxiety, satisfaction with caregiving and quality of life. Significance: This research aims to assess the feasibility, acceptability and initial efficacy of implementing the adapted PEI for alloHCT caregivers. If found feasible and acceptable, this intervention could potentially improve caregivers' ability to manage caregiving stressors and pave the way for larger-scale randomized studies and implementation.
Recruiting
Has No Placebo
Princess Margaret Cancer Centre, University Health NetworkSamantha Mayo, RN, PhD
Image of Georgetown University School of Medicine in Washington, United States.

Mosaic Website for Blood Cancer Patients

18+
All Sexes
Washington, United States
The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups). The main questions this trial aims to answer are: 1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.
Recruiting
Has No Placebo
Georgetown University School of Medicine (+3 Sites)
Image of University of Kansas Cancer Center in Kansas City, United States.

High Intensity Interval Training for Bone Marrow Transplant

18 - 80
All Sexes
Kansas City, KS
The goal of this clinical trial is to learn how a remotely monitored high-intensity interval training (REMM-HIIT) affects the cardiorespiratory fitness and physical function for patients planning to undergo stem cell transplantation. The main questions it aims to answer are: Is there a change in the participant's cardiorespiratory fitness level? Is there a change in the participant's physical function? Researchers will compare the REMM-HIIT program to a control group of participants who do not take part in the training program to see if REMM-HIIT helps improve stem cell transplantation outcomes. Participants will: * Complete cardiopulmonary exercise testing (CPET) 4 times during the study * Do basic tests to measure physical function 6 times during the study * Answer questions about their life and how they are feeling 6 times during the study * Wear a device to keep track of step counts and heart rate daily * Keep a log of every time they exercise throughout the study * Optionally, provide blood and stool samples 6 times during the study
Waitlist Available
Has No Placebo
University of Kansas Cancer Center (+2 Sites)Anthony Sung, MD
Have you considered Sitavig clinical trials? We made a collection of clinical trials featuring Sitavig, we think they might fit your search criteria.Go to Trials
Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY
The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.
Phase 2
Recruiting
Weill Cornell Medical CollegePinkal Desai, MDBristol-Myers Squibb
Have you considered Sitavig clinical trials? We made a collection of clinical trials featuring Sitavig, we think they might fit your search criteria.Go to Trials
Image of St. Jude Children's Research Hospital in Memphis, United States.

Light Therapy for Depression

8 - 18
All Sexes
Memphis, TN
The participants are being asked to be in this clinical trial, a type of research study, because the participants are going to have a hematopoietic stem cell transplant (HSCT) in the near future. Participants that get HSCT's often get depression and/or suffer from depressive symptoms, tiredness, and sleep disturbances. Primary Objective To evaluate the efficacy of BL therapy for the treatment of depression in children and adolescents undergoing hematopoietic stem cell transplant. Secondary Objectives * To evaluate the temporal effect and magnitude of BL vs. DL therapy on depression in pediatric patients undergoing HSCT. * To evaluate the efficacy of BL therapy for the treatment of fatigue in children and adolescents undergoing hematopoietic stem cell transplant. * To evaluate the response of BL therapy versus DL on sleep quality. Exploratory Objectives * To compare incidence of positive delirium screenings between those receiving BL therapy versus DL * To evaluate participant and caregiver perceptions of the acceptability, ease of use, and risks/benefits of the use of Light Therapy Glasses during HSCT utilizing qualitative interviews.
Waitlist Available
Has No Placebo
St. Jude Children's Research HospitalAndrew Elliott, MD
Have you considered Sitavig clinical trials? We made a collection of clinical trials featuring Sitavig, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security